FDA Breakthrough Therapy Designation: GSK Receives Approval For Additional Indication For Promacta
GlaxoSmithKline (GSK) announces on August 26th that the FDA approves a supplemental New Drug Application (sNDA), for the once-daily use of Promacta (Eltrombopag) in patients with Severe Aplastic Anemia (SAA), who have had an insufficient response to Immunosuppressive Therapy (IST). Promacta is a new 1st-in-class treatment option for previously treated SAA patients.
Eltrombopag is marketed under the brand name Promacta in the US and Revolade in most ex-US countries. In addition to the approval of Promacta for SAA in the US, eltrombopag is indicated for the treatment of thrombocytopenia in patients.
SAA is a rare disorder where the bone marrow fails to make enough new blood cells. There are currently no therapies approved for this indication. About forty percent (40%) of patients who do not respond to initial IST die within 5 years of diagnosis.
FDA Regulatory Actions
• Orphan Drug Designation (ODD) in May 2008 & approval in November 2008 for Thrombocytopenia
• ODD in November 2013 for Aplastic Anemia
• Breakthrough Therapy Designation (BTD) in February 2014 for cytopenias in patients with SAA who have had insufficient response to IST
• Priority Review in April 2014
• Approval for additional indication in August 2014 for patients with SAA who have had insufficient response to IST.
Please Note: “Icon Announcer” by Orion 8 [Public domain] | Wikimedia Commons.
Copyright © 2012-2014, Orphan Druganaut Blog. All rights reserved.